DOvEEgene aims to detect ovarian and endometrial cancer at an early stage to improve prognosis


MONTREAL, QC / ACCESSWIRE / October 06, 2021 / DOvEEgene – In Canada, it is estimated that around 10,000 Canadian women experience endometrial and ovarian cancer each year. The majority of affected women are diagnosed at an advanced stage, when the disease has spread and is often incurable. This happens because early-stage ovarian cancer is usually asymptomatic and late-stage symptoms of the disease are non-specific.

The clinical symptoms associated with ovarian cancer are often vague and confused with other conditions, particularly problems affecting the gastrointestinal system or simply changes in a woman’s body with age, such as gas and more frequent urination. Therefore, ovarian cancer is often referred to as the “silent killer”.

A discovery by Dr. Lucy Gilbert, director of the Department of Gynecological Oncology at McGill University Health Center, and her team hope to dramatically reduce the burden of disease and improve the lives of women. Dissatisfied with the fact that the cure rate for ovarian and endometrial cancer has not improved in the last 30 years, they developed a uterine Pap genomic test that uses a set of genes and a machine learning algorithm that hopes to find DNA cells analyze and identify mutated genes associated with these cancers – possibly the only test that is able to differentiate between cancer and non-cancer cells in pre- and postmenopausal women.

The DOvEEgene test has the potential to identify the third leading cause of cancer death in Canadian women before it’s too late, ”said Dr. Gilbert.

Dr. Gilbert and her team have just started the final clinical study of this life-saving test. Their goal is to make the DOvEEgene test, like the Pap smear, a routine part of women’s health.

Symptomatic or asymptomatic women between the ages of 45 and 70 who have a uterus are eligible to participate in the clinical trial currently taking place in Montreal, Quebec. To learn more about the testing and eligibility criteria, visit:

To support the study and to Dr. To help Gilbert and her team advance the DOvEEgene test as the standard of care, visit:

About DOvEEgene

The DOvEEgene test was designed by Dr. Lucy Gilbert and a team of dedicated Canadian doctors, professors and researchers designed to improve the early detection of women diagnosed with ovarian and endometrial cancer in hopes of improving the prognosis. This is the third and final phase of the DOvEE project, which started in 2008 and has helped thousands of women identify the symptoms of ovarian and endometrial cancer.

Press contacts

Roberta Setimi

Digital media specialist


[email protected]


View source version on

Source link


Comments are closed.